التفاصيل البيبلوغرافية
| العنوان: |
LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB) |
| المؤلفون: |
Hortobagyi, G.N., Stemmer, S.M., Burris, H.A., III, Yap, Y.S., Sonke, G.S., Hart, L., Campone, M., Petrakova, K., Winer, E.P., Janni, W., Conte, P.F., Cameron, D., André, F., Arteaga, C., Zarate, J.P., Chakravartty, A., Taran, T., Le Gac, F., Serra, P., O'Shaughnessy, J. |
| المصدر: |
In Annals of Oncology September 2021 32 Supplement 5:S1290-S1291 |
| قاعدة البيانات: |
ScienceDirect |
